Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nobelpharma America
Bethesda, Maryland, United Statesnobelpharma-am.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Nobelpharma America is a pharmaceutical company focused on the development and commercialization of treatments for rare diseases and unmet medical needs. As the United States subsidiary of Tokyo-based Nobelpharma Co., Ltd., the company leverages a specialized R&D approach to bring orphan drugs to market. Its lead commercial product, Hyftor (sirolimus topical gel), is the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex. The company is dedicated to addressing "medical gaps" by developing therapies for conditions that are often overlooked by larger pharmaceutical firms.
- Therapeutic areas
- DermatologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Aytu BioPharma
Beyond the preview
Go deeper on Nobelpharma America.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nobelpharma America.